The Global Access to Medicines Movement Peter Maybarduk +1 202 390 5375 April 15, 2011.

Slides:



Advertisements
Similar presentations
GATT AND TRIPS.
Advertisements

FTA USA-Peru and access to medicines Roberto López Linares Acción Internacional para la Salud LAC
2 nd WIPO Inter-Regional Meeting on South- South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement Cairo.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Thailand’s fight for national sovereignty - the issue of compulsory licenses Since coup Sept 2006, the new interim government issued compulsory licenses.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
Chapter 5 Intellectual Property & Internet Law
Can we create a global trade framework for health care R&D that puts patients first? James Love Consumer Project on Technology Washington, DC Presented.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
Presentation to Civil Society meeting Lusaka 1 October 2013.
Vilnius Lithuania BSc.: Biochemistry Neuropsychology J.D.: University of Oregon LL.M.:University College London Pacific Northwest National Laboratory.
Policy Issues Concerning Parallel Trade of Pharmaceutical Drugs in the United States James Love CPTech FDA Prescription Drug Importation Meeting 14 April.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
Patent Related Flexibilities in the Pharmaceutical Field
Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.
The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Intellectual Property and S&T Policy. Outline Economic perspective on S&T policy –Science, technology, information as economic resources –Market failure.
 .
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
Data Exclusivity and Access to Medicines – Empirical Evidence Hearing European Parliament: EU-India Free Trade Agreement: What Future for Patients in Developing.
Zimbabwe CSOs TRIPS and Access to medicines Aulline Mabika-Chapisa.
© 2008 West Legal Studies in Business A Division of Thomson Learning 1 BUSINESS LAW TODAY Essentials 8 th Ed. Roger LeRoy Miller - Institute for University.
Ten Years of the Doha Declaration: The State of Implementation Geneva 14 November
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
Fundamentals of Business Law Summarized Cases, 8 th Ed., and Excerpted Cases, 2 nd Ed. ROGER LeROY MILLER Institute for University Studies Arlington, Texas.
Sustainable Approaches to Opening Access to Medical Inventions James Love Wizards of OS Berlin 15 Sept 06.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
© 2007 West Legal Studies in Business, A Division of Thomson Learning Chapter 5 Intellectual Property.
UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.
UNCTAD/CD-TFT 1 Basic Features of the Multilateral Systems of Patents and Regulatory Test Data Development Dimensions of Intellectual Property Rights Hanoi.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Copyright: Knowledge Utilization Research Center Chapter 3 How Global Health Research Strengthens Research in Countries Knowledge Utilization Research.
Campana Salud para el Desarrollo Barcelona – Diciembre 2008 Judit Rius Sanjuan Knowledge Ecology International (KEI) Perspectivas futuras en la OMS.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN LESOTHO REPORT OF DAY 1 Botha Tiheli, Masello.
Presentation to Civil Society meeting Harare 21 January 2014.
WTO and the TRIPS Agreement Wolf R. MEIER-EWERT WTO Secretariat A Business-oriented overview of Intellectual Property for Law Students WIPO, Geneva 20.
Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,
Intellectual Property Law Introduction Victor H. Bouganim WCL, American University.
Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
IP Basics. What is IP? Right to EXCLUDE others from using IP Intangible assets; right to monetize them Agreement between society and creators; knowledges.
TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.
FREE TRADE AGREEMENTS Prathibha Siva Lawyers Collective HIV/AIDS Unit, India East Africa Consultation, September 2010.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Competition and Intellectual Property Protection in the Pharmaceutical Sector Alexey Ivanov Director, HSE-Skolkovo Institute for Law and Development Director,
International Intellectual Property Prof. Manheim Spring, 2007 Patent Compulsory Licensing Copyright © 2007.
Overview of presentation
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
Intellectual Property Protection and Access to Medicines
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
Prof. Martin Senftleben Vrije Universiteit Amsterdam
IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade Agreements.
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
Presentation transcript:

The Global Access to Medicines Movement Peter Maybarduk April 15, 2011

Asunto central: Como podemos asegurar el acceso a los medicamentos y a la vez optimizar la innovación biomedica?

La Competencia y el Acceso (Médicos Sin Fronteras)

Access: Looking forward 2nd, 3rd line HIV/AIDS treatment Heart disease & cancer in developing countries. Expensive biologics. Generics producers bought out Patent regimes in developing countries

“Intellectual Property” U.S. Constitution, Article 1, Section 8, Clause 8, empowers Congress: –“To promote the Progress of Science and useful Arts, by securing for limited Times to authors and inventors the exclusive Right to their respective Writings and Discoveries” Natural right to control our ideas? Artificial concept of “IP”

Patents and IP in practice But who controls IP in practice? For how long? On what terms? Patents under WTO: 20 year exclusive right to control a technology Data exclusivity: right to control clinical trial data Drug monopolies

Global IP Norm-Setting WTO / TRIPS (1995) –New patent rules for many countries Doha Declaration (2001) –Pro-public health WTO interpretation of TRIPS –See also Clinton Executive Order (2000) Free Trade Agreements –EU-India, Trans-Pacific FTA Unilateral Pressure / Sanctions

TPP: Nuevo TLC, Acuerdo Estrategico Trans-Pacifico Express goal of USA: APEC members. 21 countries; 40% of world’s population Consider precedent; shifts for global rules

(Melbourne Round)

Goal: I+A & uso racional de medicamentos –Innovation plus access and rational use. How do we get there? –Competition: Flexibilities in IP rules –Alternative financing methods for neglected diseases –Positive agenda on quality & rational use The big idea: “Delinkage.” Separating manufacturing costs from R&D.

I+A Licensing and competition –Global licensing campaign –Licensing of federally funded inventions –Medicines Patent Pool Foundation Multi-faceted innovation system –Prizes –Public research & funding –Global R&D Treaty

Las Licencias Uso gubernamental y las licencias obligatorias Autoriza la competencia con los medicamentos patentados Derecho soberano siguiendo la OMC Necesario para: Reducir costos, y así aumentar los servicios de salud y el acceso a medicamentos. Facilitar la fabricación nacional.

Compulsory licensing Authorize generic competition with a patented medicine –Patent holder receives royalties Examples: Europe, USA, developing countries Ecuador, Colombia New UNAIDS, UNDP, WHO report

Que podemos hace nosotros?

Asunto central: Como podemos asegurar el acceso a los medicamentos y a la vez optimizar la innovación biomedica?

Peter Maybarduk

Data Exclusivity EU grants marketer of new medicine 8 years exclusive use of clinical data –EC Regulation 726/2004: years Anyone wishing to market the same medicine must duplicate clinical trials Results in ten year monopolies

Counterfeit legislation Laws misrepresenting their ingredients Some bills enforce monopolies rather than protecting drug supply –IP framework vs. DRA framework EC customs regulation 1383/2003 East African bills criminalizing generics

Positive Agenda Positive agenda on medicines quality assurance and rational use –Strengthen DRAs –Combat pharmaceutical fraud –Access to medicines –International cooperation –Private sector accountability –Public participation

Data exclusivity & compulsory licensing Data exclusivity could allow for exceptions in cases of compulsory licensing –Safeguard for competition to protect health But according to DG Enterprise: –“does not foresee any exception … in case of emergency … or compulsory license” Letter to EGMA 20 Feb Impermeable ten year drug monopolies for EU members